Horizon 2020

EU Research and Innovation Framework Program

Idogen AB has been awarded a 2.9 million Euro grant from Horizon 2020, the EU’s Framework Program for Research and Innovation, for the development of the company’s tolerogenic cell therapy for the treatment of severely ill patients with hemophilia A and factor VIII inhibitory antibodies.

The EU grant SME Instruments Phase II runs over 33 months and the overall goal of Idogens approved application is to carry out preclinical safety studies, create a production capacity to produce tolerogenic cell therapy for clinical trials, and begin the first phase I / IIa study with patients with hemophilia A and inhibitory antibodies to factor VIII. The grant will be paid in parts during the term of the project.

Horizon 2020 is the largest of the EU’s research and innovation programs ever, with nearly 80 billion Euro in grants available over 7 years (2014-2020). The program promises more breakthroughs, discoveries and world news by taking good ideas from the laboratory to the market. The goal is to ensure that Europe produces world-leading research, removes barriers to innovation, and facilitates the public and private sectors to work together in delivering innovation. SME Instrument is aimed at small and medium-sized companies and allows financing of individual companies. For more information on Horizon 2020, see https://ec.europa.eu/programmes/horizon2020/.

In March 2018, Idogen received SME-oriented coaching from Dr Iordanis Arzimanoglou as part of the coaching program for Horizon 2020.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme.